Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Liabilities and Shareholders Equity: 2012-2024

Historic Liabilities and Shareholders Equity for CorMedix (CRMD) over the last 10 years, with Dec 2024 value amounting to $118.8 million.

  • CorMedix's Liabilities and Shareholders Equity rose 867.78% to $750.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 331.49%. This contributed to the annual value of $118.8 million for FY2024, which is N/A change from last year.
  • Latest data reveals that CorMedix reported Liabilities and Shareholders Equity of $118.8 million as of FY2024, which was up 91.57% from $62.0 million recorded in FY2022.
  • CorMedix's Liabilities and Shareholders Equity's 5-year high stood at $118.8 million during FY2024, with a 5-year trough of $49.3 million in FY2020.
  • In the last 2 years, CorMedix's Liabilities and Shareholders Equity had a median value of $90.4 million in 2022 and averaged $90.4 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 67.28% in 2020, then decreased by 10.02% in 2022.
  • Over the past 4 years, CorMedix's Liabilities and Shareholders Equity (Yearly) stood at $49.3 million in 2020, then surged by 39.83% to $68.9 million in 2021, then dropped by 10.02% to $62.0 million in 2022, then reached $118.8 million in 2024.